STAT Plus: Despite skepticism, Gilead’s remdesivir could become a ‘multi-year commercial opportunity’

As speculation mounts over pricing for remdesivir, a Gilead Sciences (GILD) executive suggested the experimental medicine will likely sell for much less than the nearly $30,000 it was recently valued at in a cost-effectiveness model, according to a Wall Street analyst.

At the same time, the drug maker believes remdesivir has the potential to become a “multi-year commercial opportunity,” rather than provide just a surge in sales for a year or two, Leerink analyst Geoffrey Porges wrote in an investor note sent on Monday that summarized a conversation he had with Gilead chief financial officer Andrew Dickinson.

Continue to STAT Plus

Leave a Reply